Celebrating Innovation and Excellence at Pharma USA 2024
Honoring leading professionals and organizations, the Pharma Awards USA 2024 recognized significant innovations and excellence in the pharmaceutical industry, highlighting their contributions to advancing healthcare and improving patient outcomes.
The Pharma Awards USA 2024, a prestigious event hosted by Reuters Events as part of Pharma USA 2024, concluded with resounding success, honouring outstanding achievements in the pharmaceutical sector. The awards ceremony recognized trailblazers who have demonstrated exemplary performance, innovation, and dedication to advancing healthcare outcomes.
In the category of Best Launch Campaign Award, sponsored by Atacana Group, the esteemed winner is Genmab & AbbVie for their product EPKINLY®(epcoritamab-bysp), the first and only subcutaneous bispecific antibody approved for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Dave Freundel from Genmab shared his sentiments for the win, stating, "We look forward to continuing to learn from the blood cancer community and demonstrating the utility of EPINKLY across B-cell malignancies." Freundel emphasized the commitment to furthering the development of epcoritamab across B-cell malignancies, underscoring the importance of patient-centric approaches in the industry, stating “Our hope is that the industry continues to prioritize and uplift patients and care partners in all engagement and communications strategies.”
Atacana Group, the sponsor of the category, expressed their support for fostering industry collaboration and rewarding outstanding innovations in pharmaceuticals. They highlighted the importance of supporting the Pharma Awards USA 2024, stating, "Supporting the Pharma USA Awards is our way of recognizing excellence in pharmaceutical innovation, fostering industry collaboration, and advancing healthcare outcomes through promoting and rewarding outstanding achievements."
In the category of Valuable Medical Education/Awareness Initiative Award, Eli Lilly & Co emerged as the winner for their dedication to improving healthcare and patient outcomes through independent medical education (IME). Their initiative focused on distinguishing between normal aging, mild cognitive impairment, Alzheimer's disease (AD), and other dementias, crucial for optimizing diagnosis and care. The award underscores Lilly’s commitment to making a positive impact on global health.
Responding to their win, Eli Lilly & Co stated, "Receiving this award is an honor as it recognizes the value of independent medical education (IME)." They emphasized the importance of collaboration between community healthcare providers and specialists in optimizing the diagnosis of AD in its early stages.
Genmab secured another victory in the category of Most Valuable Digital Patient Engagement Award for their innovative patient support services program, MyNavCare™. Reflecting on this accomplishment, a representative from Genmab stated, "This is a testament to both our innovative approach – which combines the power of people and cutting-edge technology to provide support to patients and care partners across digital and in-person interactions – and the unwavering dedication and commitment of our team." Looking ahead, Genmab states they are “committed to continuously improving MyNavCare™ based on patient, care partner, and provider feedback, real-world utilization and learnings, and emerging best practices.”
In the category of Driving Health Equity Award, Bayer and the American Association of Kidney Patients (AAKP) collaborated to improve patient diversity in clinical trials for chronic kidney disease (CKD). They engaged underrepresented communities, particularly Black and Hispanic populations, through grassroots Patient Ambassadors and a Standing Patient Council, which provided valuable feedback and strategic input. This innovative initiative exceeded diversity goals, ensuring that clinical trial results are more representative and generalizable, and set a new standard for inclusive and patient-centered clinical trial practices.
The Pharma Awards USA 2024 exemplify the spirit of innovation and excellence driving the pharmaceutical industry forward. With a focus on patient-centricity, collaboration, and technological advancement, these awards celebrate the pioneers shaping the future of healthcare.
With a focus on patient-centricity, collaboration, and technological advancement, these awards celebrate the pioneers shaping the future of healthcare. Find out more about the Pharma USA Awards here.